

# Technical updates of the guidelines on the Integrated Management of Childhood Illness (IMCI)

Evidence and  
recommendations for further  
adaptations

**For further information please contact:**

Department of Child and Adolescent Health and Development (CAH)

World Health Organization  
20 Avenue Appia  
1211 Geneva 27  
Switzerland

Tel +41-22 791 3281  
Fax +41-22 791 4853

e-mail [cah@who.int](mailto:cah@who.int)  
web site <http://www.who.int/child-adolescent-health>

ISBN 92 4 159348 2



**World Health  
Organization**

# Technical updates of the guidelines on the Integrated Management of Childhood Illness (IMCI)

Evidence and  
recommendations for further  
adaptations

W  
C  
I



**World Health  
Organization**

WHO Library Cataloguing-in-Publication Data

World Health Organization.

Technical updates of the guidelines on the Integrated Management of Childhood Illness (IMCI): evidence and recommendations for further adaptations.

1.Disease management 2.Drug therapy 3.Child health services 4.Delivery of health care, Integrated 5.Child 6.Practice guidelines 7.Manuals I.Title.

ISBN 92 4 159348 2

(NLM classification: WS 366)

© World Health Organization 2005

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland.

# Table of Contents

<b>Executive summary</b> .....	<b>1</b>
<b>Introduction</b> .....	<b>3</b>
<b>Acute respiratory infections</b> .....	<b>5</b>
Frequency of administration of amoxicillin treatment for non-severe pneumonia .....	5
Duration of amoxicillin treatment for non-severe pneumonia .....	5
Duration of oral cotrimoxazole therapy for non-severe pneumonia .....	6
Use of oral amoxicillin versus injectable penicillin in children with severe pneumonia .....	7
Gentamicin plus ampicillin versus chloramphenicol for very severe pneumonia .....	7
Trial of rapid-acting bronchodilators in children with wheeze and fast breathing and/or lower chest wall indrawing .....	9
<i>Summary recommendations</i> .....	10
References for acute respiratory infections .....	10
<b>Diarrhoeal diseases</b> .....	<b>12</b>
Use of low osmolarity ORS .....	12
Antibiotics in the management of bloody diarrhoea (Shigella dysentery) .....	12
Zinc in the management of diarrhoea .....	14
<i>Summary recommendations</i> .....	15
References for diarrhoeal diseases .....	15
<b>Fever/Malaria</b> .....	<b>17</b>
Antimalarials for treatment of malaria .....	17
<i>Summary recommendations</i> .....	17
References for fever/malaria .....	18
<b>Ear infections</b> .....	<b>19</b>
Chronic suppurative otitis media .....	19
Acute otitis media .....	20
<i>Summary recommendations</i> .....	20
References for ear infections .....	20

<b>Infant feeding</b> .....	<b>19</b>
Exclusive breastfeeding .....	19
Complementary feeding .....	20
Management of severe malnutrition where referral is not possible .....	21
HIV and infant feeding .....	21
<i>Summary recommendations</i> .....	24
References for infant feeding .....	24
<b>Helminth infestations</b> .....	<b>27</b>
Management of helminth infestations in children below 24 months .....	27
<i>Summary recommendation</i> .....	27
References for helminth infestations .....	28
<b>Suggested process for further adaptations of IMCI</b> .....	<b>29</b>

# Abbreviations

ACT	Artemisinin based combination therapy
AOM	Acute otitis media
ARI	Acute Respiratory Infections
ARV	Antiretrovirals
AIDS	Acquired Immunodeficiency Deficiency Syndrome
APPIS	Amoxicillin Penicillin pneumonia International Study
CAH	The Department of Child and Adolescent Health and Development
CDD	Control of Diarrhoeal Diseases
CDS	Communicable Diseases Surveillance and Response
CER	Cost-Effectiveness Ratio
CI	Confidence interval
CPE	Control, Prevention, and Eradication department of WHO
CSOM	Chronic Suppurative Otitis Media
DALY	Disability Adjusted Life Years
INF.DOC	Informational document
EBF	Exclusive breastfeeding
FAO	Food and Agricultural Organization of the United Nations
FCH	Family and Community Health
HIV	Human Immunodeficiency Virus
HQ	Headquarters
IMCI	Integrated Management of Childhood Illness
kg	kilogram
MIC	Minimum Inhibitory Concentration
Mg	milligrams
n	number
NCHS	National Center for Health Statistics (US)
NHD	Nutrition for Health and Development department of WHO
OR	Odds ratio
ORS	oral rehydration salts

p	p-values
PVC	Parasitic Diseases and vector Control unit of WHO
PNT	Post Natal Transmission
RBM	Roll Back Malaria
RHR	Reproductive Health and Research
SP	sulfadoxine-pyrimethamine
UNAIDS	Joint United Nations Programme on HIV/AIDS
UNFPA	United Nations Population Fund
UNICEF	United Nations Children's Fund
US	United States
USA	United States of America
UNU	United Nations University
WHA	World Health Assembly
WHO	World Health Organization

# Executive Summary

It is over seven years since IMCI has been introduced and much has been learnt through the adaptation and implementation processes in countries. The Department of Child and Adolescent Health and Development (CAH) and other institutions have undertaken work to evaluate the evidence base for the technical guidelines of the IMCI strategy. Research results are emerging with potential implications for updating the technical guidelines of IMCI. The technical updates are provided for use by countries whenever there are opportunities to revise the country IMCI adaptations. It will be necessary to have a series of technical updates as new research findings become available. The current technical updates have compiled new evidence to inform immediately IMCI adaptations in countries and recommend adaptations in six areas shown below.

## **Antibiotic treatment of non-severe and severe pneumonia**

For children 2 months up to 5 years with non-severe pneumonia in non-HIV countries three days in place of five days of antibiotic therapy with either oral amoxicillin or cotrimoxazole should be used. Where antimicrobial resistance to cotrimoxazole is high, oral amoxicillin is the better choice. Oral amoxicillin should be used twice daily instead of thrice daily. Injectable ampicillin plus injection gentamicin is preferable to injectable chloramphenicol for very severe pneumonia in children 2-59 months of age. For management of HIV-infected children, newly developed WHO draft treatment guidelines should be used. Children with wheeze and fast breathing and/or lower chest indrawing should be given a trial of rapid acting **inhaled bronchodilator**, before they are classified as having pneumonia and prescribed antibiotics.

## **Low osmolarity ORS and antibiotic treatment for bloody diarrhoea**

Countries should now use and manufacture low osmolarity ORS for the management of dehydration in all children with diarrhoea but keep the same label to avoid confusion.

预览已结束，完整报告链接

<https://www.yunbaogao.cn/report/index/repo>